Will molnupiravir be a game changer in our efforts to safe COVID-19 outpatients?

Pol Arch Intern Med. 2022 Jan 28;132(1):16183. doi: 10.20452/pamw.16183. Epub 2022 Jan 3.

Authors

Jacek Mrukowicz¹, Bram Rochwerg^{2

3

4}, Roman Jaeschke^{2

3}

Affiliations

¹ Polish Institute of Evidence Based Medicine, Kraków, Poland. jacekm@mp.pl
² Department of Medicine, McMaster University, Hamilton, Ontario, Canada
³ Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
⁴ MAGIC Evidence Ecosystem Foundation [www.magicproject.org]

PMID: 34978394
DOI: 10.20452/pamw.16183

No abstract available

Publication types

Letter
Comment

MeSH terms

COVID-19*
Cytidine / analogs & derivatives
Humans
Hydroxylamines
Outpatients
SARS-CoV-2

Substances

Hydroxylamines
Cytidine
molnupiravir